Selling by month
Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.
Disclosed planOne dollar scale for every month; the tallest bar is labeled
Pattern
What the filings show, past 12 months. Nothing here rates or predicts.
- Sold in 3 of the 13 calendar months from Oct 2025 to Oct 2026: Oct 2025, May 2026 and Jun 2026.
- Largest single sale: $631K (18,000 shares) of Travere Therapeutics, Inc. on Oct 31, 2025. Filing
- No sale on record before this period.
Roles from filings
Every company we track where this person has filed, newest filing first.
| Company | Title | First filing | Latest filing |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | Director | Apr 2, 2015 | Jun 16, 2026 |
| Neurocrine Biosciences Inc (NBIX) | Former Chief Financial Officer | Sep 20, 2006 | Feb 8, 2017 |
Recent filings
The last 4 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.
- Jun 12, 2026, Travere Therapeutics, Inc.: sold 10,000 shares for $501K, under a disclosed plan; 10,000 shares acquired by exercising options. 1 filing: 1
- May 19, 2026, Travere Therapeutics, Inc.: 4,000 shares awarded. 1 filing: 1
- May 15, 2026, Travere Therapeutics, Inc.: sold 3,250 shares for $141K, under a disclosed plan. 1 filing: 1
- Oct 31, 2025, Travere Therapeutics, Inc.: sold 18,000 shares for $631K, under a disclosed plan; 18,000 shares acquired by exercising options. 1 filing: 1
This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.